Evidence map›Paper›PMID 41034453›Full record

ArticleMolecular systems biology2025

Transition between cell states of sensitivity reveals molecular vulnerability of drug-tolerant cells.

Ludovic Peyre, Marielle Péré, Mickael Meyer, Benjamin Bian, Marina Moureau-Barbato, Walid Djema, Bernard Mari, Georges Vassaux, Jérémie Roux

Abstract read
In one paragraph

Article in Molecular systems biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ludovic Peyre *Université Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.
Marielle Péré *Université Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.ORCID http://orcid.org/0000-0002-7723-9365
Mickael MeyerUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.
Benjamin BianUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.
Marina Moureau-BarbatoUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.
Walid DjemaUniversité Côte d'Azur, Inria, INRAE, CNRS, GreenOwl Team, 06902, Valbonne, Sophia Antipolis, France.
Bernard MariUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.ORCID http://orcid.org/0000-0002-0422-9182
Georges VassauxUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France.ORCID http://orcid.org/0000-0002-1149-7716
Jérémie RouxUniversité Côte d'Azur, Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, CNRS UMR 7275, Inserm 1323), 06560, Valbonne, Sophia Antipolis, France. jeremie.roux@univ-cotedazur.fr.ORCID http://orcid.org/0000-0001-5712-8660

Funding

Agence Nationale de la Recherche (ANR) ANR-11-LABX-0028-01Agence Nationale de la Recherche (ANR) ANR-15-IDEX-01Agence Nationale de la Recherche (ANR) ANR-23-IAHU-007Alliance Nationale pour les Sciences de la Vie et de la Santé (AVIESAN) 2021- 2030 Cancer Control StrategyCanceropôle Provence-Alpes-Côte d'Azur (Cancéropole PACA) Prematuration EmACentre National de la Recherche Scientifique (CNRS) InnovationInstitut National de la Santé et de la Recherche Médicale (Inserm) Cellema,22CM045-00Institut National de la Santé et de la Recherche Médicale (Inserm) IMoDRez,18CB001-00
6 · The paper itself

Abstract

Drug-tolerant cells to pro-apoptotic treatments exhibit transient resistance to subsequent challenges, which can be sustained via transcriptional and translational regulations. Although persister cells have been described in other cell death modalities, how they respond to subsequent treatments that are different from the one they originate from remains less explored. Here we show that drug-tolerant cells to pro-apoptotic treatments exhibit a reduced capacity to activate caspase-8, as well as higher levels of RIPK3 protein expression. As this apoptosis-tolerant cell state exhibits features of vulnerability to necroptosis, we show that alternating from apoptotic to necroptotic treatments increases cell response compared to drug holiday or sustained treatment. To gain insights on these transitions between states of vulnerability to cell death, we developed a compartmental model explaining the emergence of drug-tolerant cell populations, and the fluxes between drug-sensitivity states. We found that drug-sensitivity states coexist in a clonal population of cancer cells with continuous transitions between them, which are sufficient to explain both the sustained resistance to repeated treatments and how alternating drug treatments ameliorates the overall treatment efficacy.

Indexed as

Antineoplastic AgentsApoptosisDrug Resistance, NeoplasmDrug ToleranceNeoplasmsCaspase 8Cell Line, TumorHumansModels, BiologicalNecroptosisReceptor-Interacting Protein Serine-Threonine KinasesAntineoplastic AgentsCaspase 8Receptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanApoptosisCancer ResistanceDrug-Tolerant PersistersMathematical ModelingNecroptosis

Identifiers

PMID41034453
PMCPMC12673137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.